Top-50 Women Longevity Leaders

AGING ANALYTICS AGENCY

www.aginganalytics.com

Top-50 Female Longevity Leaders

Executive Summary

Top-100 Longevity Leaders

Aging Analytics Agency's recent 2019 report “Top-100 Longevity Leaders” provided readers with a summary of the specific types of public and private-sector professionals directing the multi-sector Longevity industry as a whole, by identifying the top 100 individuals setting the direction of this entire multifaceted industry. This was done by measuring the impact of each leader in their field by using a unique metric for each field and then normalizing.

The report revealed that the industry is driven by a disproportionately high number of people with direct involvement in more than one sector. For example, it has for a long time proved necessary for technologists to seek public and philanthropic support via media activity and public relations.

And in order for the industry to advance from its present state of maturation, it will for the foreseeable future be necessary for members from all sectors of the industry to seek political support from those with the power to combine the diverse threads of the industry to optimal effect. This involvement of individuals in multiple sectors was reflected in lists and infographics.

In order to understand where the sources of influence lie, and how to build efficient interdisciplinary teams able to deliver meaningful milestones on the road to a fully developed global Longevity Industry, it is crucial to analyze the existing examples of accomplished leaders in this area, their backgrounds, technical skill-sets, strengths, competencies, roles in the organizations, and types of impact they have on the industry in general.

Top-100 Longevity Leaders

The report summarized the top 100 most influential leaders who have been contributing largely toward this emerging multi-faceted industry. It had the goal of providing an overall map of the global leadership scene in the areas of geroscience research and development, advanced biomedicine and the constantly-expanding Longevity Industry, their financing, and their political implementation, to serve as a benchmark tool for creating successful strategic alliances.

Lists were provided of leaders in each of these distinct sectors, and infographics were used to reveal their global geographical distribution as well as what portion of their time is spent in each of the five roles mentioned.

In addition, unlike our previous regional reports, Top-100 Longevity Leaders shone a spotlight on leaders involved with multiple sectors and spheres of activity simultaneously. The Longevity industry has reached a state of such maturity and diversity that it is entering a phase in which individuals must demonstrate leadership in more than one area.

Therefore, lists were also provided of those individuals leading multiple sectors of the industry, and infographics are used to clarify how often the same roles coincide.

Longevity is an emerging industry at the intersection of various disciplines. The market is extremely dynamic and we should investigate the trends as quickly as possible. Finding the most significant leaders — including thought leaders — is the key to understanding and prediction of development of this innovative industry.



Initial Reception

The results of this procedure produced a great deal of conversation among the Longevity industry community.

Many were surprised to find such a diverse mix of people from such diverse professional backgrounds in the same list.

Many of the people included in the list were for example surprised to find that their own impact in biomedical research, was equalled by the efforts of show business in generating publicity.

Aging Analytic Agency maintains that this is justified because an industry consists more than just the technology being produced.

As we assured readers in the Leaders report: "progress in the Longevity Industry is driven by biomedical innovation, which is in turn accelerated by political coordination formed as a response to democratic demand for Longevity solutions, which in turn is motivated by large mainstream support from public opinion."

Therefore, leadership in the Longevity Industry comes in the form of: Investors and Donors, Researchers and Academics, Entrepreneurs, Politicians and Government Officials, and Media Influencers."

All are making contributions to the coming revolution in healthy lifespan.





Women in Longevity

Some readers might also have noticed the relative underrepresentation of women in the list.

In its composition of the top 100 Longevity leaders, Aging Analytics Agency used a method which was gender-blind, and yet it revealed an industry led primarily by men, with only 17 out of 100 females rising to the status of ‘global leader’ in Longevity.

This, unfortunately, was due to forces beyond the control of Aging Analytics Agency.

Nonetheless, this male dominance is not a necessary or permanent condition of the Longevity Industry.

Indeed, the rising female demographic in the Longevity industry’s constituent fields is a worthwhile object of study in itself.

For example, it remains to be seen:

- Which areas of the industry listed in the previous report (Investors and Donors, Researchers and Academics, Entrepreneurs, Politicians and Government Officials, and Media Influencers) are the most female dominated?
- And who are the most dominant female personalities in the industry?
- In which countries are women rising in the Longevity industry?

Women, BioTech and Longevity

Women fill half of the industry's entry-level positions in biotech, but make up only 20% of leadership teams and 10% of boards, according to a study conducted by MassBio and LiftStream and published by FierceBioTech, who perform an annual rundown of the top 50 women working in biotechnology globally.

According to the US National Science Foundation, women make up 25% of tenured academics in science and engineering and more than 25% of industry scientists in US research and development Studies have confirmed that even leading female scientists are often absent from these roles.

Consider also the increased importance of the United Kingdom as a global biotech hub, as documented extensively in our Longevity in the UK regional report, and the central role of biotech research and development, to the Longevity industry, as documented in Aging Analytics Agency's previous global and regional landscape overviews.

The prevalence of women in biotech is closely linked to the propensity for women to enter STEM fields (Science, technology, engineering, and mathematics) in a given country or region.

Women currently make up 23% of those in core STEM occupations in the UK and 24% of those working in core STEM industries.

These numbers are set to increase rapidly.



Women, BioTech and Longevity

There are nearly 22,000 more women working as science and engineering technicians than in 2016. Women make up 27% of the total. In the same period the number of men increased by 52,000.

There were nearly 5,500 more women working in management roles in science, engineering and technology than in 2016. Women make up 15% of the total.

With over 900,000 women in core STEM occupations we are on track to reaching 1 million women in core STEM in 2020. The year on year increase, however, dropped below 5% for the first time in 8 years. The sector is fast growing, with overall core STEM employment increasing from 2017 by 6.3%, more than 6 times that of employment overall in the UK. An increase of 44,040 women since 2017 has for the first time taken us over 900,000.

However, with just under 200,000 additional men reversing 2017's decline, there was a 0.3% drop in the percentage of women in the core STEM workforce and growth for women is 1% lower than the growth percentage for men. Women now make up 43.2% of the total science professional workforce, but there are important differences between chemical, biological and physical sciences, with a majority of women headed for biology. We might therefore expect to see the research and development sector of the Longevity industry to have relatively large and growing female representation.

Source: FiercePharma

Women, BioTech and Longevity

According to a survey by the UK BioIndustry Association, only half of its member companies have female representation on the board.

So while the industry is attractive to women, the report indicates that very few are completing the journey right to the top.







Women, Longevity and Capital

Our Leaders report included “Donors and Investors” as one of its 5 category for a reason: The Longevity industry cannot be be bootstrapped from its present state without large capital investment in technology.

Women overall invest 40 percent less money than men do according to a survey by digital investment platform Wealthsimple. In a recent survey by Lexington Law — which asked men and women what they’d do with an extra $1,000 — men were 35 percent more likely than women to say they would invest the money.

In April 2016 Crunchbase produced a Women in Venture Report (April 2016), with the stated goal of establishing a well-defined baseline against which to measure future progress of women in the venture business. The key finding at the time was that 7 percent of the investing partners at the top 100 venture firms were women.

This might serve to explain why women were relatively underrepresented among the Investors and Donors of Aging Analytics Agency’s “Top 100 Longevity Leaders” report.



Source: Crunchbase

Women, Longevity and Capital

So should we expect women to remain underrepresented among investors in Longevity? Not necessarily.

18 months after the 2016 Crunchbase study, following a string of public disclosures on sexism, pay discrimination and sexual harassment of women in Silicon Valley, many investing firms as well as startups have taken steps to improve behavior as well as the diversity of their work forces.

As 2017 drew to a close, Crunchbase decided to re-apply the methodology from the 2016 report to see what progress, if any, might be measurable. It produced the following updated analysis:

- Among the top 100 venture firms, the percentage of women partners edged up to 8 percent from 7 percent, an increase of 17 percent.
- Eight firms in the top 100 added a female partner for the first time.
- Women now hold 15 percent of the partner roles at accelerators and corporate venture firms, a 25 percent improvement in 18 months.
- Women founded 16 micro-venture funds in the last three years, 21 percent of all the new firms in that category.
- 10 percent of venture dollars globally between 2012 and Q3 2017 went to startups with at least one woman founder.
- 16 percent of seed dollars globally between 2012 and Q3 2017 went to startups with at least one woman founder.

Furthermore women have already been increasingly active in the non-profit benefactors of Longevity-related technologies, for example comprising a small majority of the Aging 2.0 core team.



Source: Crunchbase

Women, Longevity and Capital



Global venture round counts

13 percent round counts in female founded startups (2012-Q3 2017)

Global seed round counts

18 percent round counts in female founded startups (2012-Q3 2017)

Global venture invested amounts

$46B in female founded startups (2012-Q3 2017)

Global seed invested amounts

$3.9B seed in female founded startups (2012-Q3 2017)

Source: Crunchbase

Women, Longevity and AI

Our report Longevity Industry Landscape Overview Vol 2: the business of Longevity, and Top 100 Leaders in AI in Drug Discovery emphasised the central role of AI in the Longevity and preventive medicine industries.

Over the last several years, pharmaceutical and healthcare organizations have developed a strong interest toward applying artificial intelligence (AI) in various areas, ranging from medical image analysis and elaboration of electronic health records (EHRs) to more basic research like building disease ontologies, preclinical drug discovery, and clinical trials. The demand for the ML/AI technologies, as well as for ML/AI talent, is growing in pharmaceutical and healthcare industries and driving the formation of a new interdisciplinary field — data-driven drug discovery/healthcare.

According to the data from the World Economic Forum (WEF), 78% of professionals in AI are male. Women are not only less involved in the industry, but they are less likely to hold senior positions. The problem correlates with more general gender inequality issue, namely, known underrepresentation of women in STEM (science, technology, engineering, math) jobs. These two problems need to be resolved simultaneously since they have predominantly the same roots. But according to Element AI even less share of AI developers is presented by women (12%).

No doubt the industry is suffering from the underrepresentation of women. Higher involvement of female employees and executives could give an additional boost for the whole AI branch.

In the long run, the share of women in computer sciences declined. Now we can observe sorrowful consequences of this trend in deep tech industry. But the opportunity is to use the current AI boom to engage more women. The growth of involvement of women in physics, presented on the graph, is an example of positive shifts that we need to implement in AI sector.

Until these shifts occur, we can expect to see women remain underrepresented in this area.

AI PROFESSORS BY GENDER



WOMEN ARE A SMALL MINORITY IN MACHINE-LEARNING RESEARCH



Source: Element AI

Women, Longevity and FemTech

FemTech Longevity is a component of the Longevity industry where contributions by women have a special value of their own, which is what prompted Aging Analytics Agency to release a special case study dedicated to this industry, showcasing the increasingly apparent shift in FemTech towards preventive approaches, and the emerging sector of FemTech Longevity.

FemTech refers to the emerging range of digital technologies focused specifically on women's health. The majority of the market currently consists largely of wearable devices and smartphone interfaces, connected medical devices, and hygiene products. These products, platforms, and techniques are geared towards widening female access to healthcare on a global scale, empowering as well as educating women.

Aging Analytics Agency's recent report **FemTech Healthcare Landscape Overview** offered a catalog of various forms of FemTech, ranked in order of preventiveness.

- FemTech Healthcare
- FemTech Preventive Medicine
- FemTech Longevity

It concluded with **FemTech Longevity**, which addresses age-related health issues unique to females.

The report's ultimate aim was to identify within the broader FemTech Healthcare sector those companies and technologies related to preventive medicine, Longevity, and the extension of the healthy and active period of life, as it relates to female-specific biological functions. It also sought to assess major trends within this area, and to chart the coming changes in the FemTech Preventive Medicine and FemTech Longevity sectors in the years to come.







FemTech Landscape Overview Q1 2019

FemTech Healthcare	FemTech Preventive Medicine	FemTech Longevity
Address health conditions which do not necessarily progress with age.	Address health conditions that do not necessarily progress with age.	Address health conditions that progress with age.
Palliative approach is sufficient.	Palliative approach.	Use disruptive approaches discussed in previous reports (technologies such as geroscience, regenerative medicine, etc).
No need to influence core aging processes.	Does not affect core aging processes.	Directly linked to biological aging.
MAVEN, CELES CARE, iSono Health, Jane, LOLA, THINX, flex, MONTHLY GIFT, Kasha, PMS BITES, LUNAPADS.com, CORA	FemTechNet, JOY LUX, CareNx, New Hope Fertility Center	Previum rejuvenation, Buck Live better longer., tcart FERTILITY PARTNERS, jumpstart, Center for Human Reproduction, OVA SCIENCE

The Rise of FemTech

Female-powered earnings are poised to outpace the economies of the world's biggest nation in the next 5 years. Tapping into this growth and understanding women as customers is essential to corporate prosperity.

Female Earnings, Global, 2014-2020

$18 Trillion
in 2014

$24 Trillion
by 2020

The Female economy will be bigger than the economy of China and the United States by 2020.

China's GDP (Normal) in 2020

$16 Trillion

The United States GDP (Normal) in 2020

$22 Trillion

Women-owned units will represent over 40% of registered business worldwide by 2020.

Equal male and female employment rates would boost the economy of developed nations by 5-9%. In emerging nations this could add an additional 30% to the economic output

37% of High Networth Individuals (HNIs) will e women globally controlling nearly 20% of total wealth.

In Africa, omen constitute 70% of the workforce for total crop production.

30 FemTech Healthcare Influencers

AGING ANALYTICS AGENCY

DEEP KNOWLEDGE ANALYTICS

LONGEVITY INTERNATIONAL

Jill Angelo
Genneve

Elina Berglund
Natural Cycles

Anne Boden
Starlingbank

Tania Boler
Elvie

Kate Bolton
CommsForGood

Ghela Boskovich
FemTech Global

Marija Butkovic
Women of Wearables

Judith Campisi
Buck Institute for Research on Aging

Lina Chan
Adia Health

Nicole Dahlstrom
FemTech Collective



Alexandra Fine
Dame Products

Elizabeth Gazda
Embr

Robin Farmanfarmaian
RF

Molly Hayward
Cora



Angie Lee
The Angie Lee Show

Janet Lieberman
Dame Products

Liz Lumley
Rainmaking

Elena Medo
Medolac

Devie Mohan
Burnmark

Kate Moyle
Pillow

Nuala Murphy
Moment Health

Elena Mustatea
Bold Health

Anastasia Georgievskaya
Haut.AI

Katherine Ryder
Maven Clinic

Maria Molland Selby
Thinx

Nicole Shanahan
ClearAccessIP



Tammy Sun
Carrot

Ida Tin
Clue



Jennifer Tye
Glow

Adriana Vazquez
Lilu

Female Healthspan Lagging Behind Rising Life Expectancy



The rise of the FemTech Longevity sector may partly be the result of the increasing lag between Female healthspan (the number of years free from chronic, degenerative age-related disease) and their rising lifespans.

Females have higher average lifespans and life expectancies than men. However, the number of years spent suffering from age-related diseases like dementia is also higher.

This creates an unmet need for products and services aiming to maximize female healthspan that the rising FemTech Longevity sector is striving to fulfill.

As population aging continues to steepen, and the proportion of individuals above the age of 60 years of age continues to rise, the available market for FemTech Longevity companies rises proportionally.

While the current FemTech Longevity market is dominated by products and services aiming to maintain reproductive and ovarian functionality into middle-age and old-age, we can expect to see an increasing diversity of prognostic, diagnostic and therapeutic applications aiming to intervene upon other forms of female-specific age-related health and wellbeing.

The Future of FemTech Longevity

Given the recent increase in the number of FemTech companies focused on a core Longevity component, we predict a rise in the number of FemTech companies focused on Longevity in particular.

Thus far these have tended to concentrate mainly on fertility issues, because longevity in fertility, given the present state of regenerative medicine, is a low hanging fruit and next great step for FemTech. Whereas other aspects of age-related dysfunction in female-specific bodily processes depend on a complex system of tissues and organs - such as menopause-related hormonal imbalances, for example, female age-related infertility for the most part comes down to a decline in the function of specific cells - namely, ovarian cells.

Thus, from a scientific standpoint, therapies aiming to reverse age-related infertility in women can focus on a small subset of cells rather than larger, more complex and interconnected entire bodily tissues, organs and systems, and therefore the barriers to their practical implementation are lower.

Life expectancy by gender

But progress in biomedicine, especially in the use of gene therapies and stem cell therapies to reverse aging in entire biological systems such as the endocrine system, will bring an ever wider range of age-related issues under FemTech's purview.

We should also expect to see a female-centric healthspan extending sector emerge naturally in the course of the following pursuits:

finding geroprotectors that appear to have differential effects in men and women
finding interventions (like geroprotectors and gene therapies) that upregulate genes associated with women's higher life expectancy.

Source: Center for Disease Control and Prevention (2012)

FemTech Longevity and Ovarian Rejuvenation

A tech sector focusing exclusively on female health will inevitably have some special significance for those areas of declining health which are inextricable from the aging process, such as the effects of menopause.

As such FemTech has developed much more explicit links with the Longevity industry. The identity of the FemTech sector was boosted by the creation of the Centre for Female Reproductive Longevity and Equality at the Buck Institute for Research on Aging, -- a center for FemTech in all but name.

In July, Nicole Shanahan, a Silicon Valley-based, tech-focused lawyer, entrepreneur, and philanthropist provided a gift of $6 million in seed money to open a center specifically focused on developing strategies that prevent or delay ovarian aging. The Buck Institute described it as "*the first facility anywhere in the world focused solely on reproductive equality and longevity as it relates to aging and ending the threat of age-related disease.*"

Buck professor Judith Campisi, an expert in cellular senescence and a recurring name in our previous Longevity reports, will lead early recruitment efforts at the center.

Campisi, therefore, stands at the **intersection between FemTech and the Longevity industry** and hopes to bring the full power of the Buck Institute's 19 labs and research programs in stem cells, cellular stress, and disease, mitochondria and bioenergetics, exercise, nutrition and metabolism for the center.

Judith Campisi, professor of biogerontology at the Buck Institute for Research on Aging, newly elected member of the National Academy of Sciences, and member of the SENS Research Foundation advisory board, is currently leading the recruitment efforts at the world's first center for research into reproductive longevity.

The Future of FemTech Longevity



We have already, in previous sections, touched on a number of AI-reliant FemTech solutions, such as period-tracking apps and wearables.

But the end product of a great deal of future femTech will take the form of AI-powered software as a service (SaaS), courses of monitoring and advice particularly reliant on deep learning, such as that developed by Haut.AI.

Their product is a form of deep learning-powered SaaS for skincare. They help their clients develop new skincare strategies, selecting for them skin care treatments for their individual skin type, climate, health status, geography, and other parameters , to personalize the treatments for each individual, tracking and updating these parameters over the years, to help aging skin retain a youthful look.

But they also create an interaction between between business and customer, facilitating R&D by feeding back data from 100, 000 skin images to the company for further deep learning and consequently more accurate and efficient skin care regimes.

It is expected that information collected from individual users of such services will provide researchers with large databases of metrics, offering the potential for doctors to better understand diverse aspects of women's wellness as they age.

However, for serious kinds of female age-related disease such as breast cancer, such kinds of data analytics would need huge amounts of authentic patient data - possibly from patients in many different countries and diverse racial and genetic backgrounds - for deep analysis and creation of many different patterns for successful detection. Blockchain could however help to provide data in a secure, tamper-proof way.

The Rising Female Demographic in Longevity, AI and DeepTech

Women in Longevity Reports

Aging Analytics Agency, in collaboration with its sister company Deep Knowledge analytics, is committed to revealing this rising female demographic, and has already begun to do so with the first two of gender-related reports: **Top 30 Women AI Leaders in Drug Discovery and Advanced Medicine**, and **FemTech Healthcare Landscape Overview Q1 2019**.

Although women have only made 17 out of the top 100 leaders in Longevity as of 2019, the application of a gender filter to the same procedure reveals a burgeoning population of female talent just below the surface, one which will likely become apparent earliest in geroscience research and development, and have its most marked effects in FemTech Longevity.

The Purpose of This Report

This report seeks briefly to present some of the top female leadership in Longevity. Additionally, when viewed in conjunction with the Top-100 Longevity Leaders report, it will reveal the ways in which female industry participation in Longevity differs from that of males. In particular, the type of positions and institutions in which women are most often found, and the specific sectors and fronts of the rising Longevity sphere where they are making their mark most prominently.

Female Longevity Top Talent Highlights

Daria Khaltourina

- Lead author of proposal to classify aging as disease submitted to the World Health Organization's ICD-11 task force.
- Led the task force that succeeded in having the WHO add a new extension code XT9T for "ageing-related" diseases during ICD-11.

Carol Greider

- The Nobel Prize in Physiology or Medicine 2009.
- Prize motivation: for the discovery of how chromosomes are protected by telomeres and the enzyme telomerase.

Laura Deming

- Prominent Longevity Investor
- Founded The Longevity Fund, which raised $26 million to invest on Longevity start-ups
- Joined Cynthia Kenyon's lab at the age of 12, and entered MIT at the age of 14.

Tanya Jones

- Former CEO, Alcor Life Extension Foundation
- Former Chief Operating Officer, SENS Research Foundation
- Co-founder and CEO, Arigos Biomedical

Female Longevity Top Talent Highlights

Maria Shriver

- Former First Lady of California
- Head of Alzheimer's Prevention and Preparedness Task Force
- Executive-produced The Alzheimer's Project, a four-part documentary series.

Judith Campisi

- Received international recognition for her contributions to understanding why age is the largest single risk factor for diseases.
- Her lab discovered the first biomarker for senescent cells.

Daisy Robinton

- Molecular biologist, storyteller, and lifestyle/fitness model.
- Her work described a critical function of the oncofetal gene Lin28b in driving tumorigenesis
- Discovered a novel role of the Lin28/let-7 network in embryogenesis.

Elizabeth Blackburn

- First discovered that telomeres are composed of 6-base pair segments repeated many times.
- Uncovered key mechanism used by cells to maintain telomeres.
- Identified telomerase, the enzyme that synthesizes telomere DNA.

Top-50
Women
Longevity Leaders

Top-50 Women Longevity Leaders

AGING ANALYTICS AGENCY

Investors and Donors

Media and Publicity Influencers

Politics, Policy and Governance



Entrepreneurs

Research and Academia

Top-50 Women Longevity Leaders

1. Adelaida Palla
2. Ana Maria Cuervo
3. Anne Brunet
4. Arielle Burstein
5. Bernadeane Brown
6. Cameron Diaz
7. Camilla Cavendish
8. Carol Greider
9. Cynthia Kenyon
10. Daisy Robinton
11. Daria Khaltourina
12. Diana S. Dooley
13. Edwina Rogers
14. Ekaterina Batzoglou
15. Elena Milova
16. Elizabeth Parrish
17. Elizabeth Blackburn
18. Hannah-Beth Jackson
19. Helen Whately
20. Irina Conboy
21. Janet M. Lord
22. Jill Angelo
23. Joanna Bensz
24. Judith Campisi
25. Julie Andersen
26. Katy Fike
27. Kristen Fortney
28. Laura Deming
29. Linda Partridge
30. Lindsay Cook
31. Lisa Fabiny-Kiser
32. Lora Connolly
33. Maggie Throup
34. Maria Entraigues
35. Maria Konovalenko
36. Maria Blasco
37. Maria Shriver
38. Martha Deevy
39. Nancy McPherson
40. Natasha Vita-More
41. Patricia Olson
42. Polina Mamoshina
43. Rebecca Hughes
44. Robin Farmanfarmaian
45. Sally Greengross
46. Sarah Thomas
47. Suzanne Somers
48. Suzanne Wait
49. Tanya Jones
50. Tina Woods

Top-50 Women Longevity Leaders Distribution by Region



This diagram illustrates the locations of the top Longevity women leaders across the globe. The USA and the UK retain the highest concentration of top talent, with the rest of the world, including Continental Europe, lagging behind. Reasons for this are suggested in our Key Observations section.

Top-50 Women Longevity Leaders Distribution by Category



The Longevity Industry has until recently been viewed simply as synonymous with the advancement of biotechnology. In recent years however the industry has reached a point where further advancement is only possible through a mixture of biomedical research, public persuasion, political initiative, and increased capital.

The concentration of women leaders across the 5 sectors is more diffuse than men, with a lesser proportion taking up scientific research and a greater proportion in positions of political power.

Top-50 Women Longevity Leaders
Distribution by Sector Influence (Public vs. Private)

AGING ANALYTICS AGENCY

Private Sector	Public Sector
37	13

Although still largely a private-sector pursuit,
the necessity of political initiative in moving the industry forward
is making itself apparent for the first time.

Top-50 Women Longevity Leaders
Distribution by **Primary** Activity

AGING ANALYTICS AGENCY

Entrepreneurship

30%



Research & Academia

30%



Politics and Media

40%



Top-50 Women Longevity Leaders
Distribution by the Impact on the Industry

AGING ANALYTICS AGENCY

Science and Tech Leadership (Entrepreneurs, Investors / Donors, and Research / Academia)

Politics, Policy and Governance

Media and Publicity

The above numbers describe the type of impact that top female Longevity leaders are making on the industry. The majority of effort is spent on science and tech leadership, followed by acts of political persuasion. Note that despite being downstream from media and culture, politics now occupies a greater share of Longevity leadership attention, a sign of the industry's maturation, having advanced past the publicity-seeking phase.

Investors and Donors

The Longevity Industry, being an industry dealing in extremely innovative concepts, has, especially in its earliest years, relied on a number of foundations and funds in order to lead this technological revolution. This, in turn, relies on the vision, confidence, and expertise of a tiny handful of donors and investors who have catalysed the industry.

Participants in this category have normally donated openly and explicitly in major novel interventions in aging, including sectors of the Longevity Industry falling outside the realm of biomedicine.

Media and Publicity Influencers

The Longevity Industry often came to the attention of investors and young entrepreneurs via the media and internet, which have covered these emerging technologies and trends first with great sensationalism and later with increasing seriousness.

Media and publicity are ultimately necessary factors in creating democratic demand for government involvement in these technologies, which will prove necessary if the right synergies are to be formed. Participants in this category have normally demonstrated significant thought leadership through books, articles, or major statements on influential platforms.

3 Investors and Donors
& 7 Media and Publicity Influencers

AGING ANALYTICS AGENCY

Investors and donors

Laura Deming

Rebecca Hughes

Sarah Thomas

Media and Publicity

Cameron Diaz

Lindsay Cook

Daisy Robinton

Ekaterina Batzoglou

Maria Entraigues

Robin Farmanfarmaian

Suzanne Somers

50 Women Longevity Leaders **Investors and Donors**

NAME	COMPANY	POSITION	COUNTRY	CITY
Laura Deming	Kernel, OS Fund and Braintree	Founder	USA	San Francisco, CA
Rebecca Hughes	Aging 2.0	Executive director	USA	Saint George, UT
Sarah Thomas	Aging 2.0	Innovation fellow	USA	San Francisco, CA

50 Women Longevity Leaders **Media and Publicity Influencers**

NAME	COMPANY	POSITION	COUNTRY	CITY
Cameron Diaz	The Longevity Book	Author	USA	Los Angeles, CA
Lindsay Cook	Financial times	Co-Founder	UK	Redhill
Daisy Robinton	Harvard University / Weird and Wonderful	PhD in Human Biology and Translational Medicine / Co-founder	USA	Boston, MA
Ekaterina Batzoglou	Aging Analytics Agency	Vice President of Business Development	USA	San Francisco, CA
Maria Entraigues	SENS Research Foundation	Global Outreach Coordinator	USA	Los Angeles, CA
Robin Farmanfarmaian	Actavalon	Vice President of Business Development	USA	Palo Alto, CA
Suzanne Somers	Somers Licensing Cos.	Co-Owner	USA	Malibu, CA

Entrepreneurs

The Longevity Industry is not a natural continuation of the technologies that it comprises. It is the result of a small number of visionaries who invested wisely.

Participants in this category typically have either founder status or C-level leadership roles in highly impactful companies within the Longevity Industry.

12 Entrepreneurs

AGING ANALYTICS AGENCY

Arielle Burstein

Bernadeane Brown

Elizabeth Parrish

Jill Angelo

Katy Fike

Kristen Fortney

Lisa Fabiny Kiser

Martha Deevy

Natasha Vita-More

Suzanne Wait

Tanya Jones

Tina Woods

50 Women Longevity Leaders **Entrepreneurs**

NAME	COMPANY	POSITION	COUNTRY	CITY
Arielle Burstein	Milken Institute Center for the Future of Aging	Associate director	USA	Santa Monica, CA
Bernadeane Brown	People Unlimited	Co-owner and Co-founder	USA	Scottsdale, AZ
Elizabeth Parrish	BioViva	CEO	USA	Bainbridge Island, WA
Jill Angelo	Genneve	CEO	USA	Seattle, WA
Katy Fike	Generator Ventures / Aging2.0	Partner / Co-Founder	USA	San Francisco, CA
Kristen Fortney	BioAge	CEO	USA	San Francisco, CA
Lisa Fabiny Kiser	SENS Research Foundation	Vice President of Operations	USA	San Jose, CA
Martha Deevy	Stanford Center on Longevity	Associate Director and Senior Research Scholar	USA	Stanford, CA
Natasha Vita-More	Humanity+	Executive Director	USA	Scottsdale, AZ
Suzanne Wait	Health Policy Partnership	Managing Director	UK	London
Tanya Jones	Arigos Biomedical / Alcor / SENS Research Foundation	Co-founder and Chief Executive Officer	USA	Santa Clara, CA
Tina Woods	Collider Health	Founder & CEO	UK	London

Research and Academia

Academics and researchers do the central work of the Longevity Industry, the end product of which is scientific and technological knowledge.

However, in the pursuit of this knowledge, whole new categories of research have been defined, and research has gone in entirely new directions.

For example, within the lifetimes of all the researchers and academicians listed here, geroscience R&D, and the application of advanced biomedicine to aging, was not a mainstream concept. Now it is.

Participants in the Research and Academia category have conducted academic or scientific research, including theoretical research advancing a relevant sector of the industry.

They all have either a high number of citations to their name or at least one tangible scientific breakthrough.

15 Research and Academia

Adelaida Palla

Ana Maria Cuervo

Anne Brunet

Carol Greider

Cynthia Kenyon

Elizabeth Blackburn

Irina Conboy

Janet M. Lord

Judith Campisi

Julie Andersen

Linda Partridge

Maria Blasco

Maria Konovalenko

Patricia Olson

Polina Mamoshina

50 Women Longevity Leaders **Research and Academia**

NAME	COMPANY	POSITION	H-INDEX	NUMBER OF PUBLICATIONS	COUNTRY	CITY
Adelaida Palla	Stanford University / Myoforte Therapeutics	Senior Research Scientist	4	9	USA	Stanford, CA
Ana Maria Cuervo	Einstein Institute for Aging Research	Co-Director	90	230	USA	Bronx, NY
Anne Brunet	Stanford University	Michele and Timothy Barakett Professor of Genetics	67	109	USA	Stanford, CA
Carol Greider	Johns Hopkins University	Daniel Nathans Professor / Director of Molecular Biology & Genetics	74	157	USA	Baltimore, MD
Cynthia Kenyon	Calico	Vice President of Aging Research	63	128	USA	San Francisco, CA
Elizabeth Blackburn	University of California San Francisco (UCSF)	Professor of Biology and Physiology	92	315	USA	San Francisco, CA
Irina Conboy	Berkeley Research, University of California	Professor	26	59	USA	Berkeley, CA
Janet M. Lord	Institute of Inflammation and Ageing	Director	49	223	UK	Birmingham

50 Women Longevity Leaders **Research and Academia**

NAME	COMPANY	POSITION	H-INDEX	NUMBER OF PUBLICATIONS	COUNTRY	CITY
Judith Campisi	Buck Institute for Age Research	Professor	94	272	USA	San Francisco, CA
Julie Andersen	Buck Institute for Age Research	Professor	43	97	USA	San Francisco, CA
Linda Partridge	Max Planck Institute for Biology of Ageing / UCL Institute of Healthy Ageing	Founding director / Director	93	447	UK	London
Maria Blasco	Spanish National Cancer Research Centre (CNIO)	Director	31	84	Spain	Madrid
Maria Konovalenko	Buck Institute for Research on Aging / Science for Life Extension Foundation	PHD Student / Vice President	-	-	USA	Novato, CA
Patricia Olson	CIRM	Vice President of Discovery and Translation	20	62	USA	San Anselmo, CA
Polina Mamoshina	Insilico Medicine	Head of Biomarker Development	9	31	UK	Oxford

Politics, Policy and Governance

We have often stated in this report series that political engagement is a necessary step in creating the synergies that will eventually define the Longevity Industry.

Participants in this category have been involved with either governance, lawmaking, or lobbying.

This might include government ministers, lords, senators, MPs, Congressmen, activists, campaigners, policy entrepreneurs or advisors or members of All-Party Parliamentary Groups.



13 Politics, Policy and Governance

AGING ANALYTICS AGENCY

Camilla Cavendish

Daria Khaltourina

Diana S. Dooley

Edwina Rogers

Elena Milova

Hannah-Beth Jackson

Helen Whately

Joanna Bensz

Lora Connolly

Maggie Throup

Maria Shriver

Nancy McPherson

Sally Greengross

50 Women Longevity Leaders **Politics, Policy and Governance**

NAME	COMPANY	POSITION	COUNTRY	CITY
Camilla Cavendish	All-Party Parliamentary Group for Longevity	Member	UK	London
Daria Khaltourina	Russian Academy of Sciences	Head of the Group of the Monitoring of Global and Regional Risks	Russia	Chelyabinsk
Diana S. Dooley	Partners in Care Foundation	Secretary of Health and Human Services for the State of California	USA	Sacramento, CA
Edwina Rogers	The Global Healthspan Policy Institute	Founder and CEO	USA	Washington, DC
Elena Milova	Lifesppan.io / Life Extension Advocacy Foundation	Board Member, Outreach Officer	Russia	Moscow
Hannah-Beth Jackson	Republic of California	Member of the California State Senate	USA	Santa Barbara, CA
Helen Whately	The UK Parliament/APHG	Member of Parliament for Faversham and Mid Kent / Chair Member	UK	London
Joanna Bensz	Longevity Institute	Co-founder and CEO	Poland	Warsaw
Lora Connolly	California Department of Aging	Director of the California Department of Aging	USA	Sacramento, CA
Maggie Throup	The UK Parliament	Parliamentary Private Secretary to The Department for Health & Social Care	UK	Erewash
Maria Shriver	Women's Alzheimer's Movement	Founder	USA	Los Angeles, CA
Nancy McPherson	AARP	California Director of AARP	USA	Los Angeles, CA
Sally Greengross	The UK Parliament	Intergenerational Fairness and Provision Committee	UK	London

Key Report Observations

Where do women Longevity leaders work?

In 100 Longevity Leaders we demonstrated that the Longevity industry in most of its components is concentrated in Britain and the US.

But the female element of the industry is even more concentrated in these areas, at the expense of the rest of the world including Europe.

This might be due to the concentration of women in political and media roles rather than research roles, as Britain and the US and Britain together form a political and cultural global superpower, whereas research is more diffuse globally.

In what sectors do women Longevity leaders work?

This may be where the the gender filter makes the most difference. Whereas male leadership in Longevity is concentrated overwhelmingly in research and academia, followed by a little over half as much in entrepreneurship, female leadership is much more evenly distributed across the five categories.

Therefore the circumstances of women in Longevity, neatly reflects the relative underrepresentation of women in STEM and investment.

However, much of this concentration has spread to politics, policy and government, suggesting that increased female influence might become apparent first in government before either research or investment.

Also, it should be noted that these numbers do nothing to signify the qualitative difference that female influence and input might have on the industry, such as that represented by FemTech Longevity.

Top-50
Women Longevity Leaders Profiles



Adelaida Palla

Senior Research Scientist, Stanford University, Myoforte Therapeutics

Stanford, CA, USA
Category: Research and Academia
H-index: 4
Number of publications: 9

The focus of her PhD studies was to gain a new focus on the core pluripotency factor NANOG, and extend its function to adult tissues and cancer. Experience with: Mouse models, human/mouse reprogramming, retrovirus/lentivirus transfection, primary culture/extraction of keratinocytes, mouse carcinogenesis assays, qRT-PCR, immunoblots, immunofluorescence, cloning, flow cytometry.

Earlier, she was involved in determining the interaction between two important pathways involved in polar cell planarity (PCP) during early development, the atypical cadherin Dachsous (Ds)/Fat(Ft) pathway and the Frizzled (Fz)/PCP pathway. Specifically she cloned the vectors necessary to carry out a yeast-2-hybrid assay using as bait several well-defined PCP genes in Drosophila, to be able to identify novel candidates that might be common components of Ds/Ft pathway, as well as finding their orthologues in mice by using a mouse cDNA library as a target.

Ana Maria Cuervo

Co-director, Institute for Aging Research,
Albert Einstein College of Medicine

Bronx, NY, USA
Category: Research and Academia
H-index: 90
Number of publications: 230

Albert Einstein College of Medicine

Dr. Cuervo is co-director of the Einstein Institute for Aging Research, and a member of the Einstein Liver Research Center and Cancer Center. In 2001 she started her laboratory at Einstein, where she studies the role of protein-degradation in aging and age-related disorders, with emphasis in neurodegeneration and metabolic disorders.

Dr. Cuervo's group is interested in understanding how altered proteins can be eliminated from the cells and their components recycled. Her group has linked alterations in lysosomal protein degradation (autophagy) with different neurodegenerative diseases including Parkinson's, Alzheimer's and Huntington's disease. They have also proven that restoration of normal lysosomal function prevents accumulation of damaged proteins with age, demonstrating this way that removal of these toxic products is possible. Her lab has also pioneered studies demonstrating a tight link between autophagy and cellular metabolism. They described how autophagy coordinates glucose and lipid metabolism and how failure of different autophagic pathways with age contribute to important metabolic disorders such as diabetes or obesity.

Dr. Cuervo is considered a leader in the field of protein degradation in relation to biology of aging and has been invited to present her work in numerous national and international institutions, including name lectures as the Robert R. Konh Memorial Lecture, the NIH Director's, the Roy Walford, the Feodor Lynen, the Margaret Pittman, the IUBMB Award, the David H. Murdok, the Gerry Aurbach, the SEBBM L'Oreal-UNESCO for Women in Science, the C. Ronald Kahn Distinguished Lecture and the Harvey Society Lecture. She has organized and chaired international conferences on protein degradation and on aging, belongs to the editorial board of scientific journals in this topic, and is currently co-editor-in-chief of Aging Cell.

Anne Brunet

Michele and Timothy Barakett Professor of Genetics, Stanford University

Stanford, CA, USA
Category: Research and Academia
H-index: 67
Number of publications: 109

Anne Brunet is the Michele and Timothy Barakett Endowed Professor and the co-director of the Paul F. Glenn Laboratories for the Biology of Aging at Stanford University. Dr. Brunet is interested in the molecular mechanisms of aging and longevity, with a particular emphasis on the nervous system. Her lab is interested in identifying pathways involved in delaying aging in response to external stimuli such as availability of nutrients and mates. She also seeks to understand the mechanisms that influence the rejuvenation of old stem cells. Finally, her lab has pioneered the naturally short-lived African killifish as a new model to explore the regulation of aging and age-related diseases.

The overarching goal of Brunet lab is to understand the genetic mechanisms of aging and longevity. Aging is a highly plastic process regulated by a combination of genetic and environmental factors. In her lab scientists have a long-standing interest in the genetic pathway that connects insulin to FOXO transcription factors, a central pathways to regulate lifespan from worms to humans. They use a combination of genetic, molecular, and cellular approaches to analyze the regulation and importance of FOXO transcription factors, and more generally 'longevity genes' in mammals. The Brunet Lab members are particularly interested in the role of longevity genes in the maintenance of the pool of adult neural stem cells and intact cognitive function during aging. They also use ultra-high throughput sequencing technologies to study epigenetic changes and transcriptional networks during aging.

Arielle Burstein

Associate Director, Center for the Future of Aging, Milken Institute

Santa Monica, CA, USA
Category: Entrepreneurs

Arielle Burstein is an associate director with the Milken Institute Center for the Future of Aging. She works to accelerate a needed shift in thinking about aging by collaborating with the Center's leadership and advisors, convening experts, promoting thought leadership and fostering action. Her work spans the topics of the longevity economy, innovation, purpose, and engagement of young people in issues around aging.

Burstein shapes research, produces digital communications and manages and contributes to Center publications. She joined the Institute after several years at the Massachusetts Institute of Technology AgeLab, a multidisciplinary research program, where she translated demographic change into innovative social research on aging. Her research has contributed to new products and services in retail, finance, and other industries to improve quality of life as we age. She has published academic research on the subject of technology for caregivers of people with dementia.

Bernadeane Brown

Co-Owner and Co-Founder, People Unlimited Inc.

Scottsdale, AZ, USA

Category: Entrepreneurs

PEOPLE UNLIMITED INC

Live now, live forever

Bernadeane is Co-Owner and Co-Founder of People Unlimited Inc., a social organization that supports individuals who are interested in unlimited lifespans. People Unlimited educates and informs people on emerging radical life extension science as well as information on diet, exercise and natural supplements. With all there is to know in these areas, it's difficult for any one person to keep up. People Unlimited are constantly sharing useful information and helping everyone stay as current as possible.

Bernadeane has spoken and written on radical life extension and physical immortality for over four decades. Her speaking style is fiery and focused, challenging conventional limited thinking with visionary insight and common sense honesty. Bernadeane is an expert in the habits and mindset of living an ageless lifestyle and draws on her own experience to motivate and enlighten others to break out of the box of ageism. A leading advocate for woman and immortality, she has inspired thousands of women to take on greater authority and accountability in their lives, and to look beyond the limitations of traditional roles in death-oriented society in order to redefine themselves for an unlimited future. She's the co-author of Just Getting Started: Fifty Years of Living Forever, appearing on numerous TV shows both domestically and abroad, and has touched audiences in dozens of countries.

Cameron Diaz

Author, The Longevity Book



Los Angeles, CA, USA
Category: Media and Publicity Influencers

Cameron Michelle Diaz is a retired American actress, writer and former model. She has frequently appeared in comedies throughout her career, while also earning critical recognition in dramatic films. Her accolades include four Golden Globe Award nominations, three Screen Actors Guild Award nominations, and a New York Film Critics Award. In 2013, she was named the highest-paid actress over 40 in Hollywood.

Now Cameron continues the journey she began as writer, opening a conversation with her peers on an essential topic that that for too long has been taboo in our society: the aging female body. In The Longevity Book, she shares the latest scientific research on how and why we age, synthesizing insights from top medical experts and with her own thoughts, opinions, and experiences.

The Longevity Book explores what history, biology, neuroscience, and the women's health movement can teach us about maintaining optimal health as we transition from our thirties to midlife. From understanding how growing older impacts various bodily systems to the biological differences in the way aging effects men and women; the latest science on telomeres and slowing the rate of cognitive decline to how meditation heals us and why love, friendship, and laughter matter for health, The Longevity Book offers an all-encompassing, holistic look at how the female body ages—and what we can all do to age better.

Camilla Cavendish

Member, All-Party Parliamentary Group for Longevity

London, UK
Category: Politics, Policy and Governance

Hilary Camilla Cavendish, Baroness Cavendish of Little Venice (born 20 August 1968) is a British journalist and former Director of Policy for Prime Minister David Cameron. Cavendish became a Conservative Member of the House of Lords in Cameron's resignation honours, but resigned the party Whip in December 2016 to sit as a non-affiliated peer. From 2002 until 2012 she worked at The Times where she was Associate Editor, columnist and in 2010 Chief Leader Writer.

She then moved to The Sunday Times from 2012 to May 2015. She has worked as a McKinsey management consultant, an aid worker[citation needed], and as an aide to the CEO of Pearson plc.

She helped to found the lobby group London First, and was the first CEO of the not-for-profit trust South Bank Employers' Group, which masterminded the regeneration of the South Bank of the Thames in the late 1990s.

From May 2015 to July 2016, Cavendish was head of the prime minister's policy unit at No10 Downing Street in succession to Jo Johnson. Amongst initiatives, Cavendish is credited with persuading the Prime Minister and his Chancellor about the benefits of a sugar tax; she said that the "link between sugary drinks and obesity are clear and stark". The Soft Drinks Industry Levy came into force in April 2018.

HarperCollins published Cavendish's first book Extra Time in May 2019.

Carol Greider

Daniel Nathans Professor, Director of Molecular Biology and Genetics, Johns Hopkins University

Baltimore, MD, USA
Category: Research and Academia
H-index: 74
Number of publications: 157

Carol Greider, Ph.D. received her bachelor's degree from the University of California at Santa Barbara in 1983 and a Ph.D. in 1987 from the University of California at Berkeley. In 1984, working together with Dr. Elizabeth Blackburn, she discovered telomerase, an enzyme that maintains telomeres, or chromosome ends. In 1988, Dr. Greider went to Cold Spring Harbor Laboratory where, as an independent Cold Spring Harbor Fellow, she cloned and characterized the RNA component of telomerase. In 1990, Dr. Greider was appointed as an assistant investigator at Cold Spring Harbor Laboratory, followed later by appointment to Investigator in 1994. She expanded the focus of her telomere research to include the role of telomere length in cellular senescence, cell death and in cancer.

In 1997, Dr. Greider moved her laboratory to the Department of Molecular Biology and Genetics at The Johns Hopkins University School of Medicine. In 2003 she was appointed as the Daniel Nathans Professor and Director of the Department of Molecular Biology and Genetics. At Johns Hopkins University, Dr. Greider's group continued to study the biochemistry of telomerase and determined the secondary structure of the human telomerase RNA. In addition she characterized the loss of telomere function in mice, which allowed an understanding of humans short telomere diseases such as bone marrow and other stem cell failure diseases. Dr. Greider shared the Nobel Prize in Physiology or Medicine in 2009 with Drs. Elizabeth Blackburn and Jack Szostak for their work on telomeres and telomerase. Dr. Greider currently directs a group of eight scientists studying both the role of short telomeres in age-related disease and cancer as well as the regulatory mechanism that maintain telomere length.



Cynthia Kenyon

Professor / Vice President of Aging Research,
University of California, San Francisco / Calico

London, UK
Category: Research and Academia
H-index: 63
Number of publications: 128

Cynthia Kenyon graduated valedictorian in chemistry and biochemistry from the University of Georgia in 1976. She received her PhD from MIT in 1981, where, in Graham Walker's laboratory, she was the first to look for genes on the basis of their expression profiles, discovering that DNA damaging agents activate a battery of DNA repair genes in E. coli. She then did postdoctoral studies with Nobel laureate Sydney Brenner at the MRC Laboratory of Molecular Biology in Cambridge, UK, studying the development of C. elegans. Since 1986 she has been at the University of California, San Francisco, where she was the Herbert Boyer Distinguished Professor of Biochemistry and Biophysics and is now an American Cancer Society Professor. In 1993, Kenyon and colleagues' discovery that a single-gene mutation could double the lifespan of C. elegans sparked an intensive study of the molecular biology of aging. These findings have now led to the discovery that an evolutionarily conserved hormone signaling system controls aging in other organisms as well, including mammals. Dr. Kenyon has received many honors and awards for her findings. She is a member of the US National Academy of Sciences, the American Academy of Arts and Sciences, and the Institute of Medicine and she is a past president of the Genetics Society of America. She is now the director of the Hillblom Center for the Biology of Aging at UCSF.

Daisy Robinton

PhD in Human Biology and Translational Medicine, Harvard University; Co-founder, Weird and Wonderful Inc.

Boston, MA, USA
Category: Media and Publicity Influencers

Dr. Daisy Robinton is a molecular biologist, lifestyle/fitness model. She completed her PhD in Human Biology and Translational Medicine at Harvard University in 2016 and landed on the Forbes 30 Under 30 list in 2017. Daisy was lauded for her extensive research into stem cell and liver cancer treatment, as well as her innovative charity work. Her modeling work has taken her all over the world working for brands like Neutrogena, lululemon, Powerade and Reformation. Daisy's passion for the effective translation of science has fueled her years of teaching, speaking, and consulting on numerous projects in the US and abroad, leading her to co-found Weird and Wonderful, a production company aimed at bridging the knowledge gap in science by connecting with creativity and entertainment to engage, educate and inspire people from all walks of life.

Daisy's work at Harvard University focussed on researching mechanisms of stem cell identity, with a focus on cancer and developmental biology. Daisy has also founded the 'Science in the News Spring Public Lecture Series' at Harvard to consult people on various biotech start-ups both in the US and the UK.

Daria Khaltourina

Head of the Group of the Monitoring of Global and Regional Risks, Russian Academy of Sciences

Russian Academy of Sciences

Chelyabinsk, Russia
Category: Policy, Politics and Governance

Daria Khaltourina, is a Board Member of the International Longevity Alliance and the Chair of the Board of the Russian Regional Russian NGO "Council for Public Health and Demography". She received Ph.D. in anthropology, and after a few years of academic career she gradually moved into the area of public health advocacy, including anti-liquor and anti-tobacco control in Russia and internationally. She currently works at promoting regulation beneficial for biomedical R&D, especially in the area of curing and preventing pathologies of aging. Daria is currently a coordinator of "Healthy Longevity" segment of the Russian National Technological Initiative.

Diana S. Dooley

Secretary of Health and Human Services for the State of California

Sacramento, CA, USA
Category: Policy, Politics and Governance

Diana Dooley began her professional career as an analyst at the State Personnel Board. In 1975, she was appointed to the staff of Governor Jerry Brown for whom she served as Legislative Director and Special Assistant until the end of his term in 1983. Before becoming an attorney in 1995, she owned a successful public relations and advertising agency. Dooley left her private law practice in December, 2000 to accept the appointment as General Counsel and Vice President at Children's Hospital Central California near Fresno where she established an in-house legal services program and directed the Hospital's advocacy, communications and governmental relations programs. In 2010, Diana Dooley was appointed to lead the California Health and Human Services Agency by Governor Jerry Brown. As California's designated State Unit on Aging, the California Department of Aging (CDA), which is nominally under the auspices of the California Health and Human Services Agency, has prepared the California State Plan on Aging, 2017-2021 with a focus on promoting the independence and well-being of older adults, adults with disabilities, and their families throughout the State. In three public hearings conducted to receive public comments prior to submission of this State Plan, CDA heard directly from older adults, persons with disabilities, family members, advocates, and providers about the unmet needs in their communities.

Dooley is active in civic and community affairs, having served on the Boards of Directors of the UC Merced Foundation, Blood Source of Northern California and The Maddy Institute at California State University, Fresno.

Edwina Rogers

Founder & CEO, The Global Healthspan Policy Institute

Washington, DC, USA
Category: Politics, Policy and Governance

GLOBAL HEALTHSPAN POLICY INSTITUTE

Edwina Rogers (born May 27, 1964) is an American lobbyist and former White House staff member. She is the founder and CEO of the Global Healthspan Policy Institute, the founding Executive Director and current President of the Secular Policy Institute, the CEO of the Center for Prison Reform, and a partner at the law firm of Johnson, Rogers and Clifton.After graduation from law school, Rogers worked on international trade for President George H. W. Bush at the Department of Commerce from 1989 to 1991. She practiced law in the Washington office of Balch and Bingham from 1991 until 1994, then served as General Counsel of the National Republican Senatorial Committee during the Republican take-over of the Senate in 1994. She worked for Senator Trent Lott while he was the Senate Majority Leader in 1999.

She was an Economic Advisor for President George W. Bush at the White House during 2001 and 2002 at the National Economic Council, focusing on health and social security policy. Rogers handled health policy for Senator Jeff Sessions in 2003 and 2004 before serving as Vice President of the Health Policy for the ERISA (Employee Retirement Income Security Act of 1974) Industry Committee (ERIC) in Washington, DC from May 2004 until January 2009. ERIC advocates the employee benefits and compensation interests of America’s major employers.

She worked with Senator Paul Coverdell to establish the Fair Government Foundation, a non-profit, non-partisan organization established to research and educate the public on First Amendment rights, campaign finance and political action committees, lobbying, government ethics and election law fairness issues.

Ekaterina Batzoglou

Vice President of Business Development, Aging Analytics Agency

San Francisco, CA, USA
Category: Media and Publicity Influencers

AGING ANALYTICS AGENCY

Ekaterina Batzoglou is a Vice President of Business Development at Deep Knowledge Ventures and Aging Analytics Agency, supervising activities in the United States. She is an experienced corporate attorney licensed to practice law in California and New York, with an extensive sales and marketing background. Kate built a market position by successfully developing business relationships, producing extensive analytics and efficiently closing transactions in San Francisco's ultra-competitive real estate market. At the beginning of her career, Kate was involved with international litigation when she worked for a former Pennsylvania state senator.

As a corporate attorney, Kate worked with several Fortune 500 clients. Compelled by the paradigm-shifting advances in science and technology in the fields of aging and Longevity, Kate enthusiastically joined Deep Knowledge Ventures and Aging Analytics Agency. Kate served as a Managing Editor for Longevity Industry in California: Landscape Overview 2019 report.

Elena Milova

Board Member, Outreach Officer, Lifespan.io,
Life Extension Advocacy Foundation

Moscow, Russia
Category: Politics, Policy and Governance

Elena has been a longevity activist and advocate since 2013, when she first started to organize educational events to make new evidence-based methods of healthy life extension more popular.

The last few years have seen Elena leading some successful projects in Russia, aimed at spreading the idea of healthy longevity among decision makers as well as the general public. Several years of lobbying resulted in the inclusion of her propositions in the strategic program documents of the Russian Federation related to the problems of the elderly. She is a co-author of the book “Aging Prevention for All” (in Russian, 2015), where, among other topics, she is sharing how to facilitate the adoption of the healthy lifestyle to promote the period of good health.

Elena is an Honorary Member of the International Longevity Alliance, supporting the various advocacy projects of this group. In 2015, she helped to shape and coordinate the successful crowdfunding campaign of the Major Mouse Testing Program – a study of Senolytic drug combinations on mouse lifespan.

Previously Elena has worked as a project manager in the pharmaceutical and advertisement industries, helping to promote new drugs and therapies. This experience helped her to realize that the existing therapies were not 100% effective and could not completely stop age-related diseases – which has ignited an interest for the development of innovative therapies.

Elizabeth Parrish

CEO, BioViva Sciences USA Inc.

Bainbridge Island, WA, USA
Category: Entrepreneurs

Elizabeth Parrish is the Founder and CEO of BioViva Sciences USA Inc. BioViva is committed to extending healthy lifespans using gene therapy, drugs development. To achieve this goal, BioViva has developed a comprehensive set of biomarkers of aging, which include molecular, physiological, anatomical, clinical, and qualitative markers.

Liz is known as "the woman who wants to genetically engineer you," she is a humanitarian, entrepreneur, author and innovator and a leading voice for genetic cures. As a strong proponent of progress and education for the advancement of gene therapy, she serves as a motivational speaker to the public at large for the life sciences.

Elizabeth is actively involved in international educational media outreach and is a founding member of the International Longevity Alliance (ILA). She is the founder of BioTrove Investments LLC and the BioTrove Podcasts, found at iTunes, which is committed to offering a meaningful way for people to learn about current technologies. She is also a founding member of the American Longevity Alliance (ALA) a nonprofit trade association that brings together individuals, companies, and organizations who work in advancing the emerging field of cellular and regenerative medicine with the aim to get governments to consider aging a disease.

Elizabeth Blackburn

Professor of Biology and Physiology, University of California San Francisco (UCSF)

San Francisco, CA, USA
Category: Research and Academia
H-index: 92
Number of publications: 315

Dr. Elizabeth H. Blackburn, Morris Herztein Professor of Biology and Physiology in the Department of Biochemistry and Biophysics at the University of California, San Francisco, is a leader in the area of telomere and telomerase research. She discovered the molecular nature of telomeres - the ends of eukaryotic chromosomes that serve as protective caps essential for preserving the genetic information - and the ribonucleoprotein enzyme, telomerase. Blackburn and her research team at the University of California, San Francisco are working with various cells including human cells, with the goal of understanding telomerase and telomere biology.

Blackburn earned her B.Sc. (1970) and M.Sc. (1972) degrees from the University of Melbourne in Australia, and her Ph.D. (1975) from the University of Cambridge in England. She did her postdoctoral work in Molecular and Cellular Biology from 1975 to 1977 at Yale. Throughout her career, Blackburn has been honored by her peers as the recipient of many prestigious awards. She was elected President of the American Society for Cell Biology for the year 1998. Blackburn is an elected Fellow of the American Academy of Arts and Sciences (1991), the Royal Society of London (1992), the American Academy of Microbiology (1993), and the American Association for the Advancement of Science (2000).

She was elected Foreign Associate of the National Academy of Sciences in 1993, and was elected as a Member of the Institute of Medicine in 2000. She was awarded the Albert Lasker Medical Research Award in Basic Medical Research (2006). In 2007 she was named one of TIME Magazine's 100 Most influential People and she is the 2008 North American Laureate for L'Oreal-UNESCO For Women in Science.

Hannah-Beth Jackson

Member of the California State Senate

Santa Barbara, CA, USA
Category: Policy, Politics and Governance

Hannah-Beth Jackson is an American politician currently serving in the California State Senate. A Democrat, she represents the 19th Senate District, encompassing Santa Barbara County and most of Ventura County.

Jackson served as Chair of the California Legislative Women's Caucus from 2015 to 2016. She is also a member of the California Legislative Jewish Caucus. Jackson is a former prosecutor, the co-founder of two nonprofit organizations, and also served as an adjunct professor at Antioch University.

In May 2019, Hannah-Beth Jackson to prepare for California's rapidly growing population of aging adults and protect them from falls has authored two bills. Senate Bill 228 will establish a Master Plan for Aging Californians and Senate Bill 280 will help aging and disabled adults make home modifications to reduce their risk of dangerous and often life-threatening falls. Senator has also introduced Senate Resolution 39 to declare May as Older Americans Month and raise awareness about the contributions of California's older adults as well as the challenges they continue to face.

Helen Whately

Member of Parliament for Faversham and Mid Kent; Chair of the APHG

London, UK
Category: Policy, Politics and Governance

Helen was elected as the Member of Parliament for Faversham and Mid Kent in May 2015 and is Chair of the APHG. Helen also sat on the Health Select Committee in the 2015-17 Parliament.

Helen has an established career in business and healthcare. For nearly a decade, she has worked with NHS hospitals, helping them improve care and make the most of resources. She has also advised healthcare regulators and commissioners, and worked on healthcare policy. Previously Helen ran a business unit at AOL Time Warner, negotiated deals for AOL Europe and trained as a management accountant at PricewaterhouseCoopers. Alongside her career, Helen has worked with several charities as a volunteer and advisor, and been a school governor.

Since 2015, Helen has been a vice-president of the Maidstone branch of the learning disability charity Mencap. Helen became the PPS to the Secretary of State for Education, and Minister for Women and Equalities Justine Greening. She also became the chair of the APPG for Health, and Personalised Medicine and continued to be chair of the APPG for Mental Health, and Fruit and Vegetable Farmers.

Helen supports Age UK, a registered charity, that combines the operations of the previously separate charities Age Concern and Help the Aged to form the UK's largest charity for older people, in their campaign for an energy efficiency scheme.



Irina Conboy

Professor, Berkeley Research, University of California

Berkeley, CA, USA
Category: Research and Academia
H-index: 26
Number of publications: 59

Dr. Conboy received her Ph.D. in Cellular and Molecular Immunology from Stanford University in 1998. Dr. Conboy is an assistant professor of bioengineering at UCB, and she joined the department in November of 2004. Her research is focused on the cellular signaling pathways that control the behavior of adult stem cells and understanding the age-related changes that affect this signaling. She is also an experienced rodent researcher and pioneered some of the early parabiosis research examining the role of signaling factors in aging and tissue regeneration.

Since 2005, she has been a faculty mentor for the UC Berkeley chapter of the Student Society for Stem Cell Research and a sponsor of the DeCal class Stem Cells: Science and Society. She is also a reviewer for the CIRM training grant program at UC Berkeley and a member of the peer review committee for the state of Maryland's stem cell initiative, an invited peer reviewer for the Neurogenesis and Cell Fate Study Section at the NIH, and a reviewer for the Nathan Shock Center of Excellence in the Basic Biology of Aging. Irina Conboy received the CIRM New Faculty Award in 2008, the Glenn Award for Research in Biological Mechanisms of Aging in 2008, and the New Scholar in Aging award from Ellison's Medical Foundation in 2005.

Janet M. Lord

Director, Institute of Inflammation and Ageing

Birmingham, UK
Category: Research and Academia
H-index: 49
Number of publications: 223

UNIVERSITY OF BIRMINGHAM | INSTITUTE OF INFLAMMATION AND AGEING

Janet Lord is director of the MRC-ARUK Centre for Musculoskeletal Ageing Research and the Institute of Inflammation and Ageing, both located within the new Queen Elizabeth super Hospital which opened in the summer of 2011.

Janet's research focuses on the innate immune system, the body's front line defense against infection, and how the efficiency of this system is affected by ageing and stress, the latter including physical trauma and emotional stress such as bereavement. She is also interested in how the ageing of the immune system predisposes adults to chronic inflammatory diseases such as Rheumatoid Arthritis and COPD and the muscle wasting associated with age and these conditions. In all of her work she aims to translate research findings into interventions, whether lifestyle (exercise, diet) or pharmacological, to improve immunity and health in old age.

Professor Lord is also a leading member of the NIHR SRMRC, researching the impact of major trauma on the immune system and how this differs with age. Find out more about the work of the research centre on the SRMRC website.

Janet has published over 200 research papers and reviews in the fields of immunescence, chronic inflammatory disease and neuroendocrineimmune biology. She was elected a Fellow of the Academy of Medical Sciences in 2015 and awarded the Lord Cohen Medal by the British Society for Research into Ageing in 2013. Her research is currently funded by grants from MRC, Arthritis Research UK, NIHR, The Scar Free Foundation and the European Commission.

Jill Angelo

CEO, Genneve

Seattle, WA, USA
Category: Entrepreneurs

Jill Angelo is the CEO and Founder of Genneve whose mission is to improve the lives of women in midlife and menopause. Genneve is a first-of-its-kind online clinic for women in menopause, which uses AI and telehealth technology to improve access to education, practitioners and products personalized for a woman's symptoms today and long-term care.

Prior to running Genneve, Jill had a 20-year career in technology at both Great Plains Software and Microsoft. Most recently, she spent 15 years at Microsoft in executive roles such as Chief of Staff to the CMO, Director of Global Media, and Product Management for Emerging Markets. Jill recently joined the Board of Directors for Special Olympics of Washginton.

Named as one of Inc. Magazine's 2016 Most Impressive Women Entrepreneurs, Jill is a driving force for bringing effective health solutions, information and resources to women in the most vibrant years of their lives. She has a background in launching products from the ground-up and scaling brands in thrifty and creative ways. Jill is combining her passion for women's health with her business-building experience in the tech industry to build the go-to solution for women in midlife and menopause.

Joanna Bensz

Co-founder and CEO, Longevity Institute

Warsaw, Poland
Category: Policy, Politics and Governance

Joanna Bensz is a Co-founder and CEO at Longevity Institute, a non-profit organization providing an open knowledge platform for identifying, highlighting and supporting solutions to today's healthy longevity sector challenges and opportunities. The Longevity Institute is the first private institute in Poland in the field of healthy aging, healthy lifestyle and the use of the latest scientific achievements, artificial intelligence and blockchain technology in this sector. One of their missions is to create a bridge between business, academia, financial institutions and start-up companies in the area of healthy longevity and health preservation. The Longevity Institute brings together a global community of cross sector experts, organizations and entrepreneurs with an interest in healthy longevity, age science, preventive healthcare and longevity economy.

Joanna has a significant experience in the management and business development of international companies from the industrial and technological sectors in Poland and the region of Central and Eastern Europe. She was associated with the American Chamber of Commerce in Poland for many years.

Joanna has a master's degree in German philology and a diploma in international and strategic marketing at the Dublin Business School in Ireland. She is also a graduate of the AMP management program at the IESE Business School at the University of Navarra in Barcelona and Warsaw.

Judith Campisi

Professor, Buck Institute for Age Research

San Francisco, CA, USA
Category: Research and Academia
H-index: 94
Number of publications: 272

Campisi received a PhD in Biochemistry from the State University New York at Stony Brook and completed postdoctoral training at the Harvard Medical School. As an assistant professor at the Boston University Medical School, she became interested in the control of cellular senescence and its role in tumor suppression and aging. She joined the Lawrence Berkeley National Laboratory as a Senior Scientist in 1991. She established a second laboratory at the Buck Institute in 2002. At both institutions, she established a broad program to understand various aspects of aging, with an emphasis on the interface between cancer and aging. The Campisi laboratory has made several pioneering discoveries in these areas, and her research continues to challenge and alter existing paradigms.

Judith Campisi, has received international recognition for her contributions to understanding why age is the largest single risk factor for developing a panoply of diseases, ranging from neurodegeneration to cancer. Her highly acclaimed research integrates the genetic, environmental and evolutionary forces that result in aging and age-related diseases, and identifies pathways that can be modified to mitigate basic aging processes. The Campisi lab found evidence that senescent cells can disrupt normal tissue functions and, ironically, drive the progression of cancer over time. Senescent cells also promote inflammation, which is a common feature of all major age-related diseases. Campisi is collaborating with many other research groups at the Buck Institute to examine other suspected influences of senescent cells on other diseases of aging. Her research is shedding light on anti-cancer genes, DNA repair mechanisms that promote longevity, molecular pathways that protect cells against stress, and stem cells and their role in aging and age-related disease.

Julie Andersen

Professor, Buck Institute for Age Research

San Francisco, CA, USA
Category: Research and Academia
H-index: 43
Number of publications: 97

Andersen was born in Great Falls, Montana. She earned a doctorate in Neuromolecular Biology at the University of California, Los Angeles (UCLA). She completed a postdoctoral fellowship at Harvard Medical School and Massachusetts General Hospital before going to the University of Southern California as an assistant then an associate professor at the Andrus Gerontology Center. She joined the Buck Institute in 2000.

As a renowned expert on Parkinson's disease, Julie K. Andersen, PhD, is pursuing a wide array of leads toward treatments for this complex neurodegenerative disorder. She has identified several early risk signals for Parkinson's, an age-related illness that causes a progressive decline in movement and muscle control. The symptoms can include shaking hands and difficulty with walking.

Amongst the early risk signals identified by Andersen are elevated levels of iron and declining amounts of a protective antioxidant called glutathione. Recently, the Andersen lab has also discovered valuable clues by examining the roles of enzymes and other proteins involved in nerve cell degeneration.

The Andersen lab is also involved in identifying potential biomarkers for Parkinson's that may allow early interventional therapy.

Katy Fike

Partner, Generator Ventures /
Co-Founder, Aging2.0 / PhD Gerontologist

San Francisco, CA, USA
Category: Entrepreneurs

Katy Fike is a founding partner of Generator Ventures and co-founder of Aging2.0, a global innovation network and startup accelerator program. Katy is a PhD gerontologist, former investment banker and systems engineer. Recently named one of Fast Company's 100 Most Creative People in Business, Katy is a sought after speaker on topics related to innovation and aging and has been featured in national media including NPR, PBS NewsHour, Bloomberg TV, Wall Street Journal, BusinessWeek, Forbes, TIME, TechCrunch and Huffington Post. Katy has taken the stage at conferences such as South by Southwest, Consumer Electronics Show, Boomer Venture Summit, American Senior Housing Association, National Investment Center for Seniors Housing and Senior Living 100. Katy is on the Board of Directors of the American Society on Aging and the Family Caregiver Alliance. Katy earned her doctorate in gerontology from the USC Davis School of Gerontology and her undergraduate degree in Systems Engineering from University of Virginia. Katy has taught Gerontology at the university level and her research on care transitions has been published in peer-reviewed journals and presented at several national conferences.

Kristen Fortney

CEO and Co-founder, BioAge Labs

San Francisco, CA, USA
Category: Entrepreneurs

Kristen Fortney is Founder and CEO of BIOAGE, a venture-backed startup that couples large omics datasets with machine learning to measure human aging and accelerate drug discovery to treat aging associated diseases. The company's ultimate goal is to combat the suffering and disability caused by all aging-related diseases, and to restore both the quality and quantity of life in old age.

Kristen received her PhD from the University of Toronto in 2012 and completed her postdoctoral training at Stanford University, where she was an Ellison Medical Foundation / American Federation for Aging Research fellow. She is an expert at developing novel bioinformatics approaches that harness large amounts of data to shed light on the mechanisms of aging and age-related diseases. Her research has focused on computational drug discovery, biomarkers of aging, and the genetics of exceptional human longevity.

Laura Deming

Partner and Founder, The Longevity Fund

San Francisco, CA, USA
Category: Investors and Donors

Laura Deming is the daughter of John and Tabitha Deming; she grew up in New Zealand. Deming and her brother, Trey, were homeschooled; she says she taught herself "calculus and probability and statistics, and French literature and history." At age 8, Deming became interested in the biology of aging, and at age 12 she joined the lab of Cynthia Kenyon at the University of California, San Francisco. Kenyon successfully increased the lifespan of the worm C. elegans by a factor of ten through genetic engineering.Deming was accepted to MIT at age 14 and studied physics,but later dropped out to accept the $100,000 Thiel Fellowship and start a venture capital firm.Deming was one of only two women in the 2011 initial class of Thiel Fellows. Deming is a partner at and founder of The Longevity Fund, a venture capital firm focused on aging and life extension.The firm raised $4 million in its first fund and $22 million for its second fund, in 2017. The Longevity Fund investments include Unity Biotechnology, which develops senolytic drugs targeting diseases of aging, Navitor Pharmaceuticals, and Metacrine. In 2018, Deming launched Age1, a four-month startup accelerator program focused on founders creating longevity companies.The program graduated its first class of six on October 10, 2018, with companies including Fauna Bio, a startup using the biology of hibernation to aid in heart attack and stroke recovery, and Spring Discovery, focused on accelerating aging therapeutic research with machine learning. In August 2018, Deming also began advising the newly launched Pioneer Fund, a fund designed to find talent and "lost Einsteins" around the world, for projects in longevity.

Linda Partridge

Founding director, Max Planck Institute for Biology of Ageing in Cologne; Director, the UCL Institute of Healthy Ageing

London, UK
Category: Research and Academia
H-index: 93
Number of publications: 447

After three years of postdoctoral research at the University of York, Linda Partridge was Demonstrator, Lecturer, Reader and finally Professor at the University of Edinburgh. After many years in Scotland, in 1994 she became Professor of Biometry, University College London. Linda Partridge is both a founding director of the new Max Planck Institute for Biology of Ageing in Cologne and Director of the UCL Institute of Healthy Ageing.

Linda Partridge's research is directed to understanding both how the rate of ageing evolves in nature and the mechanisms by which healthy lifespan can be extended in laboratory model organisms. Her work has focussed in particular on the role of nutrient-sensing pathways, such as the insulin/insulin-like growth factor signalling pathway, and on dietary restriction. Her current work is directed to developing pharmacological treatments that ameliorate the human ageing process to produce a broad-spectrum improvement in health during ageing. Linda also studies the genetics of ageing and age-related diseases, such as Alzheimer's disease and Parkinson's disease.

She is the recipient of numerous awards, including a DBE for services to science. Linda was elected to the Academy of Medical Sciences in 2004, and was awarded the Linnean Society of London's prestigious Darwin-Wallace Medal in 2008. In March 2009, the UKRC announced Dame Linda as one of six Women of Outstanding Achievement in Science, Engineering and Technology. She was awarded with Foreign Honorary Membership from the American Academy of Arts and Sciences in 2010.

Lindsay Cook

Co-Founder, Financial times

Redhill, UK
Category: Media and Publicity Influencers

A consultant to several publishing companies, Lindsay is also an award-winning financial journalist and author. Co-founder of MoneyFightClub.com, which offers financial well-being workshops for major British companies. Writes the Money Mentor column for the Weekend Financial Times and appears regularly on Share Radio. Lindsay was a speaker at the Women at the Top Summit in September 2016. She also appeared at the FT Weekend Live Festival.

Lindsay was the first woman to be appointed Business Editor of The Times and subsequently moved into newspaper and magazine management.

She is also the deputy chair of the Citizens Advice Bureau in West Sussex.

She is the co-author of Money Fight Club (Harriman House) with Anne Caborn, a practical guide to saving money the smart way and tackling the High Street rip-offs - from supermarkets to banks and insurance companies. She has also launched a website: moneyfightclub.com, which has loads of resources including downloadable letters of complaint for a wide range of problems.

She also wrote Working Mum: The Survival Guide helping parents to find their way through the intricacies of flexible working and employment law and The Money Diet: Three Months to Financial Fitness, which was serialised in three newspapers.

Lisa Fabiny Kiser

Vice President of Operations, SENS Research Foundation

San Jose, CA, USA
Category: Entrepreneurs

Lisa Fabiny Kiser, Vice President of Operations at SENS Research Foundation, is a Bay Area transplant from the Midwest and a dedicated scientist and administrator. Lisa's educational background is in the Life Sciences, in which she earned her Bachelor's Degree from Otterbein College in 2009. Her industry experience ranges from microbiology, stem cell analytics, flow cytometry, to quality assurance, finance, operations, and HR.

Lisa joined SRF in 2010 as a volunteer in the laboratory, and was hired on in the administrative department in early 2012, where she excelled in finance and operations. She is invested in advancing rejuvenation biotechnologies and using her skills in organizational management to move SRF forward in this burgeoning field. Lisa currently spends her time running the operations and outreach departments at SRF – adding fundraising, event planning, and marketing to her current skill set. She hopes to continue to help SRF lead the charge in advancing rejuvenation biotechnology against the diseases of aging through funding research, forming new therapies, influencing global health policy, and creating a dialogue between top scientists and regulators in the industry.

Lora Connolly

Director of the California Department of Aging

Sacramento, CA, USA
Category: Policy, Politics and Governance

Lora Connolly is director of the California Department of Aging, which administers the Older Americans Act services through the state's 33 Area Agencies on Aging, as well as the Medicaid HCBS Waiver (which annually serves approximately 11,000 older adults), and certifies more than 240 Adult Day Health Care Centers for Medicaid participation. The California Department of Aging developed the current State Plan on Aging 2017-2021 with a focus on promoting the independence and well-being of older adults, persons with disabilities, and their families. The State Plan outlines specific goals, objectives, and strategies that CDA believes it can achieve with existing resources.

For the past 16 years, Connolly has also co-managed a series of federal Administration on Aging Dementia Grants, in partnership with the state's regional Alzheimer's organizations.

When Gavin Newsom, California's new governor, began his term among a growing crisis of senior poverty in the state, Connolly served as cooauthor of Governor Newsom's Master Plan on Aging, one of his top three priorities mentioned in his State of the State Address.

Maggie Throup

Chair of the APPG on Obesity, Heart Disease; the secretary for the APPG on Human Trafficking and Modern Slavery

Erewash, UK
Category: Policy, Politics and Governance

Maggie Throup is a British Conservative Party politician. She was first elected as the Member of Parliament (MP) for Erewash in the 2015 general election.

After obtaining an Honours degree in Biology from Manchester University, she began her career at Calderdale Health Authority as a medical laboratory scientist, spending seven years in the role and gaining professional qualifications in Haematology. Remaining in the health sector, Maggie moved into medical diagnostics sales and marketing with a pharmaceutical company before establishing her own marketing company.

Maggie first entered politics through her involvement with a community campaign to save an area of green belt from development and has since gone on to lead a number of similar campaigns, most notably opposing the construction of the East Midlands HS2 Hub on green belt at Breaston.

In Parliament, Maggie has become a passionate advocate for the wider use of diagnostic testing in order to reduce the amount of antibiotics that are wrongly prescribed, as well as establishing and Chairing the All Party Parliamentary Group on Obesity. In 2015, Maggie was elected to serve on the House of Commons Health Select Committee, and has also previously served on the Scottish Affairs Select Committee. Following the Government reshuffle in January 2018, she was appointed Parliamentary Private Secretary to the Ministerial team at The Department for Health and Social Care.

Maria Entraigues

Global Outreach Coordinator, SENS Research Foundation

Los Angeles, CA, USA
Category: Media and Publicity Influencers

Maria Entraigues Abramson is currently Global Outreach Coordinator for the SENS Research Foundation co-founded by Dr. Aubrey de Grey. She's been part of SRF since its founding days and before that, part of Methuselah Foundation (co-founded by Dave Gobel and Aubrey de Grey). She is also a science and technology communicator and one of the leading voices in the field of Longevity. Her passion and strong involvement in science and technology, combined with her skills in Public Relations and networking, positioned her as one of the main "connectors" in the field, in charge of building new critical relationships, spreading the word about the mission and driving donations. She is also a singer, actress, composer, journalist and pilot. Maria is a radical-change believer and spends her multifaceted life working on facilitating disruptive change to help the world. You can find her giving a scientific talk, singing live for thousands of people, composing and acting for a Hollywood film, doing music journalism, or flying an airplane. But her main goal is to make sure one day aging doesn't mean to get sick. She is also co-founder of Longevity Bridge, dedicated to developing resources for optimal health - currently developing new assays to measure important biomarkers of aging. She currently sits in the Boards of the Coalition for Radical Life Extension, International Longevity Alliance, California Transhumanist Party and Lifeboat Foundation. She is also a member of The Three Hundred. She is also co-director of the Longevity Film Competition. An international film competition created to help convey the importance of addressing age related disease. She's constantly being interviewed in the subject of radical life extension and Cryonics throughout the media, as well as presenting in conferences and being featured internationally on different documentaries and TV shows. In her music career, she's been privileged to have toured the world as a singer with some of the biggest pop and rock stars, recorded countless hours of professional studio sessions and composing and acting for big Hollywood and international movies.

Maria Konovalenko

Vice President, Science for Life Extension Foundation

Novato, CA, USA
Category: Research and Academia

Maria Konovalenko is studying biology of aging in a joint PhD program between University of Southern California and the Buck Institute for Research on Aging. Maria has been involved in fighting aging since 2008. She is one of the organizers of the Genetics of Aging and Longevity Conference series. Maria has been part of team at the Science for Life Extension Foundation, a Moscow-based non-profit, since 2008 and has been raising funding for longevity and regenerative medicine, neuroscience, systems biology, and related sciences aimed at studying the mechanisms of aging and searching for methods to increase human longevity research from both government and private sources.

Konovalenko's background is in molecular biophysics, she got both her Bachelor's and Master's degrees from Moscow Institute of Physics and Technology.

Maria's goal is to make people live as long and as healthy as possible using the advances of science and technology.

Maria Blasco

Director, Spanish National Cancer Research Centre (CNIO)

Madrid, Spain
Category: Research and Academia
H-index: 31
Number of publications: 84

Maria A. Blasco obtained her PhD in 1993 at the Centro de Biología Molecular "Severo Ochoa" under the supervision of M. Salas. That same year, Blasco joined the Cold Spring Harbor Laboratory in New York (USA) as a Postdoctoral Fellow under the leadership of C. W. Greider. As a postdoc she isolated one of the telomerase essential genes and generated the first telomerase deficient mouse model, which served to demonstrate the importance of telomerase in telomere maintenance, chromosomal instability and disease. In 1997, she returned to Spain to start her own research Group at the Centro Nacional de Biotecnología in Madrid. She joined the Spanish National Cancer Research Center (CNIO) in 2003 as Director of the Molecular Oncology Programme and Leader of the Telomeres and Telomerase Group. In 2005, she was also appointed Vice-Director of Basic Research at CNIO. Since June 2011, she is the CNIO Director.

For more than 20 years, Blasco´s work has focused in demonstrating the importance of telomeres and telomerase in cancer, as well as in age-related diseases. Blasco has published more than 250 papers in international journals and has an h-index of 81. Her achievements have been recognized by the following international and national awards: Josef Steiner Cancer Research Award, Swiss Bridge Award for Research in Cancer, Körber European Science Award, the EMBO Gold Medal, the "Rey Jaime I" Award in Basic Research, the Fundación Lilly Preclinical Research Award, and the "Santiago Ramón y Cajal" National Award in Biology. Blasco holds two Doctorate Honoris Causa from the Universidad Carlos III of Madrid and from Universidad de Alicante and in October 2017 she received the Scientific Merit Award of the Generalitat Valenciana.

Maria Shriver

Founder, Women's Alzheimer's Movement

Los Angeles, CA, USA
Category: Policy, Politics and Governance

Maria Shriver is an NBC journalist and author who founded the Women's Alzheimer's Movement. She served as first lady of California from 2003 to 2011. In 2010 Maria organized the first ever March to End Alzheimer's, a multigenerational 5K "march" in Long Beach, CA. The inspiring event raised over $270,000 dollars for the Alzheimer's Association and served as the kick-off to The Women's Conference, then the nation's premier gathering of women. In March 2017, The Alzheimer's Association awarded Shriver with its first-ever Lifetime Achievement Award, recognizing her for using her voice and her platforms to significantly move the needle on the public's awareness of this disease.

The Women's Alzheimer's Movement is a nonprofit organization that is dedicated to raising awareness about women's increased risk for Alzheimer's and to educating the public — women and men — about lifestyle changes they can make to protect their brain health. Through their annual campaigns and initiatives, they also raise dollars to fund women-based Alzheimer's research at leading scientific institutions, so that they can better understand this mind-blowing disease and hopefully get closer to a cure. To date, The Women's Alzheimer's Movement has awarded over $800,000 in grants to leading scientists and research institutions across the U.S. who are committed to conducting women-based Alzheimer's research.

In 2019 Maria Shriver will lead a new Alzheimer's Prevention and Preparedness Task Force where she will be joined in the group by "the most renowned scientists and thinkers" who'd help the California state prepare for the Alzheimer's disease commonly associated with aging.

Martha Deevy

Associate Director, Senior Research Scholar,
Stanford Center on Longevity

Stanford, CA, USA
Category: Entrepreneurs

Martha Deevy joined the Stanford Center on Longevity in January, 2009 and serves as Associate Director and Senior Research Scholar, where she focused on re-imagining how we plan for retirement and how we live in retirement. She has over 20 years of management experience in Silicon Valley technology and financial services companies in senior executive positions at Apple, Charles Schwab and Intuit. Having held positions in marketing, business development, product development, strategic planning, finance and IT, she has developed a strong general management background that she successfully used to define and shape the businesses she managed.

Martha has also served on the boards of directors of a number of publicly traded and non-profit organizations. She received an M.B.A. in Finance and Management Information Systems from University of Minnesota and a B.A. in Quantitative Economics from University of Illinois.

Nancy McPherson

California State Director, AARP

Los Angeles, CA, USA
Category: Policy, Politics and Governance

Nancy, an alum of Leadership Southern California 2016, is the State Director for AARP. Two years ago Nancy was enticed to move back to her home state as the interim state director for AARP, and the challenge became inspiration. She was responsible for creating a new vision for AARP's work, new relationships with state leaders, and burgeoning work in local communities – skills that are now honed in Leadership Southern California's revised curriculum focused on leading collaboration and building strategic partnerships.

AARP is a nonprofit, nonpartisan organization, with a membership of nearly 38 million that helps people turn their goals and dreams into 'Real Possibilities' by changing the way America defines aging. With staffed offices in all 50 states, the District of Columbia, Puerto Rico, and the U.S. Virgin Islands, AARP works to strengthen communities and promote the issues that matter most to families such as healthcare security, financial security and personal fulfillment. AARP also advocates for individuals in the marketplace by selecting products and services of high quality and value to carry the AARP name. As a trusted source for news and information, AARP produces the world's largest circulation magazine, AARP The Magazine and AARP Bulletin. AARP does not endorse candidates for public office or make contributions to political campaigns or candidates.

Natasha Vita-More

Executive Director, Humanity+

Scottsdale, AZ, USA
Category: Entrepreneurs

Dr. Vita-More is recognized for her work concerning the impacts of technology and the human future. The scope of her work covers science, technology, and sociopolitical issues. Her personal aim is to accelerate regenerative generations, promote the mindset of ageless thinking, and innovate lifespans beyond biological limitations.

She has been called “an early adapter of revolutionary changes” (Wired) and a “role model for superlongevity” (Village Voice) and featured in over two dozen televised documentaries on emerging technology, human enhancement, and life extension. Her pioneering writing on “Ageless Thinking”, her innovation “Primo Posthuman” a cross platform whole body prosthetic, and her current work on the “Regenerative Generation” have vigorously established a strong incentive to many. Her multi-media and narrative have received Special Recognition at Women in Video, exhibition at the US Film Festival, Filmex LA, London Contemporary Art Museum, Memphis Museum, Niet Normal in Germany, the Moscow Film Festival, and GOGBOT, The Netherlands.

In the field of design, the prototype “Primo Posthuman", 1997 produced the seminal whole-body prosthetic that unmasks the probable outcomes of regenerative biology. The further iteration of this project has resulted in “Platform Diverse Body” (2012) and “Substrate Autonomous Persons” (2012), which offer insight into how technological innovation mitigates physiology.

In the field of science, her research proved to be a scientific breakthrough in long-term memory in the field of cryobiology.

Patricia Olson

Vice President of Discovery and Translation, CIRM
San Anselmo, CA, USA
Category: Research and Academia
H-index: 20
Number of publications: 62

Patricia Olson, Ph.D., serves as the Vice President, Discovery & Translation, at the California Institute for Regenerative Medicine (CIRM) responsible for the development, implementation and outcomes of CIRM's Discovery and Translation funding programs. Previously, she served in a variety of positions at CIRM including Executive Director, Scientific Affairs, responsible for the development, review, implementation and management of CIRM's research funding program.

Prior to joining CIRM, Dr. Olson served in a variety of positions at Chiron Corporation (now Novartis) including Vice President, Protein Therapeutics Research and Vice President, Portfolio Management and Strategic Planning, R&D. While at Chiron, she participated in the research and development of several products including two marketed products. Patricia is an inventor on 22 issued U.S. patents and an author of 31 peer-reviewed publications and book chapters. Dr. Olson received her Ph.D. in Biochemistry and Biophysics from the University of California at Berkeley and her B.S. in Cellular Biology (magna cum laude) from the University of Michigan, Ann Arbor.

Polina Mamoshina

Head of Biomarker Development,
Insilico Medicine
Oxford, UK

Category: Research and Academia

H-index: 9

Number of publications: 31

Insilico Medicine 英科智能

Polina Mamoshina is a senior research scientist at Insilico Medicine, Inc, a Baltimore-based bioinformatics and deep learning company focused on reinventing drug discovery and biomarker development and a part of the computational biology team of Oxford University Computer Science Department.

Polina graduated from the Department of Genetics of the Moscow State University. She was one of the winners of GeneHack a Russian nationwide 48-hour hackathon on bioinformatics at the Moscow Institute of Physics and Technology attended by hundreds of young bioinformaticians. Polina is involved in multiple deep learning projects at the Pharmaceutical Artificial Intelligence division of Insilico Medicine working on the drug discovery engine and developing biochemistry, transcriptome, and cell-free nucleic acid-based biomarkers of aging and disease. She recently co-authored seven academic papers in peer-reviewed journals.

Rebecca Hughes

Executive Director, Aging 2.0

San Francisco, CA, USA
Category: Investors and Donors

Rebecca Hughes is the Executive Director at Aging2.0, which strives to accelerate innovation to address the biggest challenges and opportunities in aging. Aging2.0's international, interdisciplinary and intergenerational community has grown to 40k+ innovators across 20+ countries. Their volunteer-run chapter network, which spans 80+ cities, has hosted more than 550 events around the world to bring attention to their mission, educate others and find solutions around the Grand Challenges and opportunities in aging.

Rebecca Hughes responsibilities span across multiple focus areas, including the oversight our chapter community, corporate partners and operations. Over the course of the four years she has been part of the Aging2.0 team, Rebecca has developed a passion and appreciation for aging innovation. She looks forward to continued work within the space.

Robin Farmanfarmaian

Vice President, Business Development,
Actavalon

Palo Alto, CA, USA

Category: Media and Publicity Influencers

Robin Starbuck Farmanfarmaian is a professional speaker, entrepreneur and angel investor working on companies in cutting edge tech poised to impact 100M people or more. With over 125 speaking engagements in 12 countries, she educates audiences on technology, the future of healthcare, patient empowerment, building thought leadership, and more. Her first book, “The Patient as CEO: How Technology Empowers the Healthcare Consumer”, is a #1 Best Seller on Amazon. Her 2nd book published in March, 2019: "The Thought Leader Formula: Strategically Leverage Your Expertise to Drive Business & Career Goals".

Sally Greengross

Treasurer, All-Party Parliamentary Group for Longevity

London, UK
Category: Politics, Policy and Governance

Sally Greengross, Baroness Greengross, OBE (born 29 June 1935) is a British politician. Awarded an OBE in the 1993 New Year's Honours, Sally Greengross was raised to the peerage as Baroness Greengross, of Notting Hill in the Royal Borough of Kensington and Chelsea in the year 2000, sitting as a crossbencher. Greengross was Director General of Age Concern England from 1987 until 2000; also until 2000, she was joint Chair of the Age Concern Institute of Gerontology at King's College London, and Secretary General of Eurolink Age. Her appointments include that of Chair of the Advisory Groups for the English Longitudinal Study of Ageing (ELSA) and the New Dynamics of Ageing (NDA); and Chief Executive of the International Longevity Centre - UK, President of the Pensions Policy Institute and Honorary Vice President of the Royal Society for the Promotion of Health. She has been an independent crossbench member of the House of Lords since 2000 and chairs three All-Party Parliamentary Groups: Corporate Social Responsibility, Intergenerational Futures: Old & Young Together and Continence Care. She is the Vice Chair of the All-Party Parliamentary Group on Dementia and Ageing and Older People, and is Treasurer of the All-Party Parliamentary Group on Equalities. In December 2006, it was announced that she would be a Commissioner for the Equality and Human Rights Commission.She holds honorary doctorates from a number of British universities. She has been awarded an Honorary Doctor of Letters (DLitt) degree by the University of Ulster in 1994, Brunel University in 2002, University of Keele in 2004. She was awarded a Doctor of the University (DUniv) degree by the Kingston University in 1996, the Open University and Leeds Metropolitan University in 2002. She was awarded an Honorary Doctor of Laws (LLD) by the University of Exeter in 2000.

Sarah Thomas

Innovation Fellow, Aging 2.0

San Francisco, CA, USA
Category: Investors and Donors

Sarah Thomas joined the Aging2.0 team as the Genesis Innovation Fellow. Serving also as Director of Global Innovations for Genesis Rehabilitation Services/Genesis Healthcare, one of the largest post-acute care providers in the country, Sarah is passionate about innovation and improving the lives of older adults.

Sarah has dedicated 15 years to aging services, including five years consulting for emerging technology companies. Most recently, she served as the Legislative Affairs Liaison for Hallmark Rehabilitation. Sarah combines her Occupational Therapy background with her operational, clinical and entrepreneurial experience to inspire passionate changes to the current systems in the elder care environment.

Sarah currently is appointed to the Administration and Management Special Interest Section Committee for the American Occupational Therapy Association, an active member of LeadingAge, the California Association of Healthcare Facilities, and is on the Telehealth workgroup for The National Association for the Support of Long Term Care. She is a contributing author for the recent book Readmission Prevention – Solutions Across the Provider Continuum by Josh D Luke and is a sought-after speaker for national conferences.

Suzanne Somers

Writer, Publicity Influencer



Malibu, CA, USA
Category: Media and Publicity Influencers

Suzanne Somers (born Suzanne Marie Mahoney, October 16, 1946) is an American actress, author, singer, businesswoman, and health spokesperson. She appeared in the television role of Chrissy Snow on Three's Company and as Carol Foster Lambert on Step by Step.

Somers later became the author of a series of self-help books, including Ageless: The Naked Truth About Bioidentical Hormones (2006), about bioidentical hormone replacement therapy. She has released two autobiographies, four diet books, and a book of poetry.

She has been criticized for her views on some medical subjects and her advocacy of the Wiley Protocol, which has been labelled as "scientifically unproven and dangerous". Her promotion of alternative cancer treatments has received criticism from the American Cancer Society.

Suzanne Somers is a regular keynote presenter at RASDFest.

Suzanne Wait

Managing Director, Health Policy Partnership

The Health Policy Partnership

London, UK
Category: Entrepreneurs

In a health policy career spanning more than 15 years, Suzanne has helped to run multi-stakeholder initiatives in numerous disease areas. She has broad knowledge of the challenges of intersectoral working and the need for sustainable and person-focused healthcare systems.

Having begun her career at IRDES, the French national centre for health economics in Paris, she worked as Global Health Economist at Novartis Pharma and later as Associate Director of Health Outcomes for Europe and the UK at Bristol-Myers Squibb. She went on to become Director of Research at the International Longevity Centre – UK. She was also a founding member of the European Nutrition for Health Alliance, and is a member of the Coalition to Eradicate Viral Hepatitis in Asia Pacific (CEVHAP).

Suzanne has authored numerous peer-reviewed papers, book chapters and policy reports. She spent five years teaching at the School of Public Policy at University College London, is a former Nuffield Trust Research Fellow at the Judge Institute of Management at Cambridge University, and was Adjunct Professor at the University of Strasbourg.

Suzanne has a Master of Public Health from Columbia University and a PhD in Public Health from the University of Strasbourg. In 2006, she completed a Nuffield Trust-funded post-doctoral fellowship at the University of Cambridge, which looked at benchmarking health systems and public involvement in healthcare.

Tanya Jones

Co-founder and CEO, Arigos Biomedical
(Alcor and SENS Research Foundation)

Santa Clara, CA, USA
Category: Entrepreneurs

Tanya Jones is the Chief Executive Officer and co-founder of Arigos, a startup that is developing a methodology for the long term banking of organs for the transplant industry and the Chief Operating Officer of SENS Research Foundation, a nonprofit working to research, develop and promote comprehensive regenerative medicine solutions for the diseases of aging.

As the CEO of Arigos, Tanya Jones secured early funding for Arigos, including becoming the first company funded by Breakout Labs, the Thiel Foundation's most recent effort to effect disruptive innovation in science and technology. She is currently in the process of securing another round of funding which will enable Arigos to complete proof-of-concept recovery experiments on human-scale organs stored at liquid nitrogen temperatures.

As the COO of SENS Research Foundation, Tanya manages the contracts and financing for its collaborative extramural research projects with such leading research institutions as Harvard, Cambridge, Yale, Oxford, Wake Forest Institute for Regenerative Medicine, The Buck Institute for Research on Aging, and Rice University. In addition, she leads the strategy and execution of the Foundation's finance, human resources and real estate activities.

Tina Woods

Founder & CEO, Collider Health

London, UK
Category: Entrepreneurs

Tina Woods is founder of Collider Health, a health innovation catalyst that works with organisations of all shapes and sizes to think and do differently and transform health with meaningful impact. Tina is chair of Future Health Collective, a multi-disciplinary, cross-industry group geared to foster collaboration and radical innovation in areas of unmet need in health and social care. Tina is passionate about helping young businesses and new ventures succeed and looking to pioneer more socially-driven collaborations. She has established relationships with leading incubators, accelerators, investors, digital health startups, clinical innovators and tech corporates. Before founding Collider Health Tina spent many years in the agency world, helping big pharma and other healthcare corporates educate doctors and create awareness around new drugs, treatments and diagnostics. Alongside her commercial work, Tina runs a social enterprise on science innovation, Collider SCIENCE, working with leading scientists, innovators and designers to equip young people with the skills and confidence to become inventors and change agents in science and medicine.

Collider Health is a health innovation catalyst that works with organisations of all shapes and sizes to think and do differently and transform health with meaningful impact, via collaborative ventures and strategic partnerships. The pace of innovation needs to keep up with today's relentless quest for better health solutions at lower cost. Companies need to be more agile and evolve business models to avoid being left behind or becoming extinct. Innovators across the spectrum of wellcare and sickcare, in large and small organisations, need support to connect ideas with money and collaborate better together.



AGING ANALYTICS AGENCY

www.aginganalytics.com | info@aginganalytics.com

Aging Analytics Agency is the world's premier provider of industry analytics on the topics of Longevity, Precision Preventive Medicine and Economics of Ageing, and the convergence of technologies such as AI, Blockchain, Digital Health and their impact on the healthcare industry, renowned for its development of sophisticated comparative analytical frameworks allowing for practical and tangible forecasts to be applied to industries that are otherwise too complex for standard analytical approaches to be used in a relevant way. The company provides strategic consulting services in fields relating to Longevity, and currently serves as the primary source of analytics and data for the UK All-Party Parliamentary Group for Longevity.

The agency focuses on the convergence of technological megatrends, deep science and advanced technologies, and the development of multidimensional analytical frameworks that possess a level of complexity proportional to the industries and domains they are analysing, was a necessary requirement in order to conduct effective industry analysis, forecasting and benchmarking of the Longevity, Advanced Biomedicine and Precision / Preventive / Personalised Medicine at the minimum level of relevance and pragmatism.

These ongoing proprietary analytics have consistently been accompanied by the production of vast open-access landscape overviews on the Longevity industry of particular geographic regions, and on specific technological domains, in many cases more than 1,000 pages in length. The purpose of producing these broad landscape overviews is to serve as a kind of analogue of Wikipedia and the Encyclopedia Britannica for the Longevity industry, widely disseminating ongoing developments in the global Longevity Industry in order to promote its continued growth, expansion and refinement. But, they also serve an important secondary purpose as well: laying the groundwork for a comprehensive understanding of the entire scope of the industry across the globe, and facilitating a greater comprehension of the specific industry players, their activities, and their interconnections. In other words, these reports establish the necessary foundation upon which more targeted, relevant and complex analyses can be executed.

Today, these analytical methodologies have evolved to incorporate 3-D frameworks where metrics and submetrics can be visualized simultaneously, as well as the development of "timeline machines" that allow to review the changing state of a company's strength in specific areas ranging from scientific validation to business development, R&D, etc. to be visualized over time, and projected into the future based on the statistical properties of its past behaviour.

AGING
ANALYTICS
AGENCY

Link to the Report: https://www.aginganalytics.com/top-50-women

E-mail: info@aginganalytics.com | **Website: www.aginganalytics.com**